Interpretation of the 2022 American Academy of Pediatrics guidelines for the management of hyperbilirubinemia in newborn infants
YANG Jing-Li, WANG Jian-Hui
Department of Neonatology, Children's Hospital of Chongqing Medical University/National Clinical Research Center for Child Health and Disorders/Ministry of Education Key Laboratory of Child Development and Disorders/Chongqing Key Laboratory of Pediatrics, Chongqing 400014, China
Abstract The American Academy of Pediatrics updated the guidelines for the management of hyperbilirubinemia in the newborn infants with a gestational age of ≥35 weeks in September 2022. Based on the evidence over the past 18 years, the guidelines are updated from the aspects of the prevention, risk assessment, intervention, and follow-up of hyperbilirubinemia in the newborn infants with a gestational age of ≥35 weeks. This article gives an interpretation of the key points in the guidelines, so as to safely reduce the risk of bilirubin encephalopathy and unnecessary intervention.
YANG Jing-Li,WANG Jian-Hui. Interpretation of the 2022 American Academy of Pediatrics guidelines for the management of hyperbilirubinemia in newborn infants[J]. CJCP, 2023, 25(1): 11-17.
YANG Jing-Li,WANG Jian-Hui. Interpretation of the 2022 American Academy of Pediatrics guidelines for the management of hyperbilirubinemia in newborn infants[J]. CJCP, 2023, 25(1): 11-17.
Olusanya BO, Teeple S, Kassebaum NJ. The contribution of neonatal jaundice to global child mortality: findings from the GBD 2016 study[J]. Pediatrics, 2018, 141(2): e20171471. PMID: 29305393. DOI: 10.1542/peds.2017-1471.
American Academy of Pediatrics Subcommittee on Hyperbilirubinemia. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation[J]. Pediatrics, 2004, 114(1): 297-316. PMID: 15231951. DOI: 10.1542/peds.114.1.297.
Kemper AR, Newman TB, Slaughter JL, et al. Clinical practice guideline revision: management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation[J]. Pediatrics, 2022, 150(3): e2022058859. PMID: 35927462. DOI: 10.1542/peds.2022-058859.
Hynes S, Moore Z, Patton D, et al. Accuracy of transcutaneous bilirubin versus serum bilirubin measurement in preterm infants receiving phototherapy: a systematic review[J]. Adv Neonatal Care, 2020, 20(6): E118-E126. PMID: 32366804. DOI: 10.1097/ANC.0000000000000738.
Yang ST, Liu FC, Chen HL. Comparison of transcutaneous and serum bilirubin before, under, and after phototherapy in term and late-preterm infants[J]. Kaohsiung J Med Sci, 2019, 35(11): 715-724. PMID: 31436020. DOI: 10.1002/kjm2.12121.
Maisels MJ, Clune S, Coleman K, et al. The natural history of jaundice in predominantly breastfed infants[J]. Pediatrics, 2014, 134(2): e340-e345. PMID: 25049352. DOI: 10.1542/peds.2013-4299.
Riskin A, Tamir A, Kugelman A, et al. Is visual assessment of jaundice reliable as a screening tool to detect significant neonatal hyperbilirubinemia?[J]. J Pediatr, 2008, 152(6): 782-787. PMID: 18492516. DOI: 10.1016/j.jpeds.2007.11.003.
Setia S, Villaveces A, Dhillon P, et al. Neonatal jaundice in Asian, white, and mixed-race infants[J]. Arch Pediatr Adolesc Med, 2002, 156(3): 276-279. PMID: 11876673. DOI: 10.1001/archpedi.156.3.276.
Maisels MJ, Deridder JM, Kring EA, et al. Routine transcutaneous bilirubin measurements combined with clinical risk factors improve the prediction of subsequent hyperbilirubinemia[J]. J Perinatol, 2009, 29(9): 612-617. PMID: 19421200. DOI: 10.1038/jp.2009.43.
Fawaz R, Baumann U, Ekong U, et al. Guideline for the evaluation of cholestatic jaundice in infants: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition[J]. J Pediatr Gastroenterol Nutr, 2017, 64(1): 154-168. PMID: 27429428. DOI: 10.1097/MPG.0000000000001334.
Harpavat S, Garcia-Prats JA, Anaya C, et al. Diagnostic yield of newborn screening for biliary atresia using direct or conjugated bilirubin measurements[J]. JAMA, 2020, 323(12): 1141-1150. PMID: 32207797. PMCID: PMC7093763. DOI: 10.1001/jama.2020.0837.
Slaughter JL, Kemper AR, Newman TB. Technical report: diagnosis and management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation[J]. Pediatrics, 2022, 150(3): e2022058865. PMID: 35927519. DOI: 10.1542/peds.2022-058865.
Wickremasinghe AC, Risley RJ, Kuzniewicz MW, et al. Risk of sensorineural hearing loss and bilirubin exchange transfusion thresholds[J]. Pediatrics, 2015, 136(3): 505-512. PMID: 26283777. DOI: 10.1542/peds.2014-3357.
Wu YW, Kuzniewicz MW, Wickremasinghe AC, et al. Risk for cerebral palsy in infants with total serum bilirubin levels at or above the exchange transfusion threshold: a population-based study[J]. JAMA Pediatr, 2015, 169(3): 239-246. PMID: 25560920. DOI: 10.1001/jamapediatrics.2014.3036.
Das RR, Naik SS. Neonatal hyperbilirubinemia and childhood allergic diseases: a systematic review[J]. Pediatr Allergy Immunol, 2015, 26(1): 2-11. PMID: 25229699. DOI: 10.1111/pai.12281.
Bugaiski-Shaked A, Shany E, Mesner O, et al. Association between neonatal phototherapy exposure and childhood neoplasm[J]. J Pediatr, 2022, 245: 111-116. PMID: 35120988. DOI: 10.1016/j.jpeds.2022.01.046.